Raymond James Financial Inc. Buys Shares of 41,592 Integra LifeSciences Holdings Co. (NASDAQ:IART)

Raymond James Financial Inc. acquired a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 41,592 shares of the life sciences company's stock, valued at approximately $943,000. Raymond James Financial Inc. owned 0.05% of Integra LifeSciences at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in IART. Nisa Investment Advisors LLC raised its stake in Integra LifeSciences by 599.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock worth $74,000 after buying an additional 2,800 shares during the period. Nordea Investment Management AB raised its position in shares of Integra LifeSciences by 4.1% during the fourth quarter. Nordea Investment Management AB now owns 127,908 shares of the life sciences company's stock worth $2,919,000 after purchasing an additional 5,032 shares during the period. Choreo LLC lifted its holdings in shares of Integra LifeSciences by 29.9% in the 4th quarter. Choreo LLC now owns 22,274 shares of the life sciences company's stock worth $500,000 after purchasing an additional 5,123 shares in the last quarter. Empowered Funds LLC acquired a new stake in Integra LifeSciences in the 4th quarter valued at $180,000. Finally, Romano Brothers AND Company bought a new stake in Integra LifeSciences during the 4th quarter valued at $204,000. Institutional investors own 84.78% of the company's stock.

Integra LifeSciences Stock Up 6.2 %

NASDAQ:IART traded up $1.12 on Wednesday, hitting $19.19. The stock had a trading volume of 1,223,982 shares, compared to its average volume of 1,049,461. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $34.41. The firm's fifty day simple moving average is $22.63 and its two-hundred day simple moving average is $22.31. The stock has a market cap of $1.48 billion, a P/E ratio of -213.20, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. The business had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences's quarterly revenue was up 11.5% compared to the same quarter last year. During the same period last year, the company posted $0.89 earnings per share. Analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

Separately, Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Integra LifeSciences presently has an average rating of "Hold" and an average price target of $23.00.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.